logo

Biotech Stocks Facing FDA Decision In February

Gilead Sciences
Gilead Sciences

The FDA decision on Gilead Sciences Inc.’s (GILD) BIC/FTC/TAF, a triple-drug cocktail for the treatment of HIV-1 infection in adults will be known by February 12, 2018.

BIC/FTC/TAF is a fixed dose combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide.

A combination of Emtricitabine and Tenofovir Alafenamide as a single tablet under the name Descovy is already approved by the FDA.

GILD closed Thursday’s (Jan.25) trading at $81.19, down 0.14%.

Share